SpaceX Falcon 9 rocket plume blossoms over Florida | Space photo of the day for Feb. 18, 2026

SpaceX launched the NASA/SpaceX Crew-12 mission on Feb. 13 at 5:15 a.m. EST from Cape Canaveral atop a reusable Falcon 9, carrying NASA astronauts Jessica Meir and Jack Hathaway, ESA's Sochie Adenot and cosmonaut Andrey Fedyaev; the Crew Dragon docked with the ISS on Feb. 14 to begin an eight-month Expedition 74 rotation. NASA released a dramatic photographer’s image of the Falcon 9’s exhaust plume; the piece notes the ISS had been operating with a three-person skeleton crew after a Jan. 8 medical evacuation of four Crew-11 astronauts.

Analysis

Market structure: SpaceX's routine Crew-12 launch reinforces durable cost leadership for reusable Falcon 9 services, pressuring smaller launch providers and raising effective supply of LEO capacity. Public winners are satellite builders and defense primes (Maxar/MAXR, Northrop/NOC, Lockheed/LMT, RTX) that sit downstream or on government budgets; losers are pure-play small-launchers (Rocket Lab/RKLB) and speculative space-tourism names where pricing power will compress by an estimated 15–30% on per-kg launch rates over 12–36 months.

Risk assessment: Tail risks include a high-profile Falcon anomaly prompting FAA/DoD groundings and insurance premium spikes (losses >20% for exposed equities) and US/Russia geopolitical frictions affecting ISS operations. Immediate impact (days) should be muted; watch 30–90 day contract awards and insurance filings; medium-term (3–12 months) pricing displacement and consolidation; long-term (1–3 years) structural growth in satellite deployments offsets lower launch prices but centralizes market share.

Trade implications: Favor quality aerospace/defense long exposures (MAXR, NOC, LMT, RTX) with 6–36 month horizons and selective short or hedge exposure to small-launch pure-plays (RKLB) using 3–9 month options to benefit from expected volatility and price compression. Rotate away from consumer cyclicals into industrials/defense by 1–3% portfolio overweight; use pair trades (long MAXR, short RKLB) to isolate launch-vs-manufacturing dynamics.

Contrarian angles: Consensus underestimates regulatory/insurance tail risk and overestimates uniform upside across “space” names — the better risk/reward is concentrated suppliers of payloads and government contractors, not launch-only equities. Historical parallels (post-2010 launch commoditization) suggest 12–24 month consolidation; set tight stop-losses and size positions small (1–3%) given binary event risk.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Maxar Technologies (MAXR) within 2 weeks, target +12–18% upside over 6–12 months driven by increased small-sat procurement; hedge with a 6–9 month ATM call if you prefer leverage; place a hard stop at -12%.
• Add 1–2% long positions in Lockheed Martin (LMT) and/or Northrop Grumman (NOC) (split allocation) as defensive, contract-backed space exposure; hold 12–36 months and trim if government backlog indicators fall >20% vs. trailing 12-month average.
• Implement a 0.5–1% short (or buy 3–6 month OTM puts) on Rocket Lab (RKLB) to express expected 15–30% near-term pricing pressure for small-launch services; size small due to volatility and set stop-loss if RKLB rallies >20% from entry.
• Enter a pair trade: long MAXR 2% / short RKLB 1% to capture divergence between payload demand growth and launch-price compression over next 12 months; close or rebalance if MAXR underperforms by >15% relative to RKLB or after major FAA/DoD contract announcements within 90 days.